Hasil Pencarian - Tahamtan Ahmadi

  • Menampilkan 1 - 10 hasil dari 10
Perbaiki Hasil
  1. 1
    786 Dose selection for DuoBody®-PD-L1×4-1BB (GEN1046) using a semimechanistic pharmacokinetics/pharmacodynamics model that leverages preclinical and clinical data

    786 Dose selection for DuoBody®-PD-L1×4-1BB (GEN1046) using a semimechanistic pharmacokinetics/pharmacodynamics model that leverages preclinical and clinical data oleh Manish Gupta, Maria Jure-Kunkel, Alexander Muik, Özlem Türeci, Tahamtan Ahmadi, Ugur Sahin, Ulf Forssmann, Marc Presler, Eleni Lagkadinou, Gaurav Bajaj, Fereshteh Nazari, Craig Thalhauser

    Diterbitkan 2021-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    493 First-in-human phase 1/2 trial to evaluate the safety and initial clinical activity of DuoBody®-CD40×4–1BB (GEN1042) in patients with advanced solid tumors

    493 First-in-human phase 1/2 trial to evaluate the safety and initial clinical activity of DuoBody®-CD40×4–1BB (GEN1042) in patients with advanced solid tumors oleh Homer Adams, Patricia LoRusso, Juanita Lopez, Melissa Johnson, Özlem Türeci, Tahamtan Ahmadi, Ugur Sahin, Jessica Bauman, Daniel Haggstrom, Eleni Lagkadinou, Gaurav Bajaj, Yali Fu, Kristoffer Rohrberg

    Diterbitkan 2021-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    1181 GEN1042-mIgG2a, an Fc-inert mouse-human chimeric variant of GEN1042 (DuoBody®-CD40x4–1BB), exhibits in vivo antitumor activity and peripheral immune modulation

    1181 GEN1042-mIgG2a, an Fc-inert mouse-human chimeric variant of GEN1042 (DuoBody®-CD40x4–1BB), exhibits in vivo antitumor activity and peripheral immune modulation oleh Karsten Pilones, Maria Jure-Kunkel, Homer Adams, Alexander Muik, Tahamtan Ahmadi, Ugur Sahin, Oezlem Tuereci, Kristina Nuermberger, Angelica Sette, Monique Luijten, Maren Köhne, Jasja Wolthoorn, Sina Fellermeier-Kopf

    Diterbitkan 2023-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    813 Combination of HexaBody-CD27 with PD-(L)1 blockade potentiates single-agent activity leading to enhanced human T-cell effector functions in vitro

    813 Combination of HexaBody-CD27 with PD-(L)1 blockade potentiates single-agent activity leading to enhanced human T-cell effector functions in vitro oleh Jordan Blum, Alexander Muik, Isil Altintas, Friederike Gieseke, Aras Toker, Esther Breij, Tahamtan Ahmadi, Ugur Sahin, Kristel Kemper, Oezlem Tuereci, Kristina Nuermberger, Sina Fellermeier-Kopf, Andrea Imle, Anna-Lena Krause, Lidia Daszkiewicz

    Diterbitkan 2023-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    561 DuoBody®-PD-L1×4–1BB (GEN1046) induces superior immune-cell activation, cytokine production and cytotoxicity by combining PD-L1 blockade with conditional 4–1BB co-stimulation

    561 DuoBody®-PD-L1×4–1BB (GEN1046) induces superior immune-cell activation, cytokine production and cytotoxicity by combining PD-L1 blockade with conditional 4–1BB co-stimulation... oleh Maria Jure-Kunkel, Rachelle Kosoff, Mark Fereshteh, Alexander Muik, Isil Altintas, Friederike Gieseke, Kristina Schödel, Theodora Salcedo, Saskia Burm, Aras Toker, Lena Kranz, Mathias Vormehr, David Eisel, Özlem Türeci, Esther Breij, Tahamtan Ahmadi, Ugur Sahin

    Diterbitkan 2020-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma

    Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma oleh Tineke Casneuf, Xu Steven Xu, Homer C. Adams, III, Amy E. Axel, Christopher Chiu, Imran Khan, Tahamtan Ahmadi, Xiaoyu Yan, Sagar Lonial, Torben Plesner, Henk M. Lokhorst, Niels W.C.J. van de Donk, Pamela L. Clemens, A. Kate Sasser

    Diterbitkan 2017-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    516 Peripheral and tumoral immune activity in the expansion part of the first-in-human DuoBody®-PD-L1×4–1BB (GEN1046) trial

    516 Peripheral and tumoral immune activity in the expansion part of the first-in-human DuoBody®-PD-L1×4–1BB (GEN1046) trial oleh Andrés Cervantes, Victor Moreno, Maria Jure-Kunkel, Suresh Ramalingam, Emiliano Calvo, Patricia LoRusso, Brandon Higgs, Suzana Couto, Nora Pencheva, Santiago Ponce Aix, Daniel Cho, Alexander Muik, Özlem Türeci, Tahamtan Ahmadi, Ugur Sahin, Elena Garralda, Ulf Forssmann, Eleni Lagkadinou, José Trigo Pérez, Muhammad Furqan

    Diterbitkan 2021-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    An Fc-inert PD-L1×4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation

    An Fc-inert PD-L1×4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation oleh Alexander Muik, Isil Altintas, Friederike Gieseke, Kristina B Schoedel, Saskia M Burm, Aras Toker, Theodora W. Salcedo, Dennis Verzijl, David Eisel, Christian Grunwitz, Lena M Kranz, Mathias Vormehr, David P.E. Satijn, Mustafa Diken, Sebastian Kreiter, Kate Sasser, Tahamtan Ahmadi, Özlem Türeci, Esther C.W. Breij, Maria Jure-Kunkel, Ugur Sahin

    Diterbitkan 2022-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity

    DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity oleh Maria Jure-Kunkel, Homer C Adams III, Kate Sasser, Mark Fereshteh, Alexander Muik, Isil Altintas, Friederike Gieseke, Aras Toker, Özlem Türeci, Tahamtan Ahmadi, Ugur Sahin, Dennis Verzijl, Kristina B Schoedel, Jordan M Blum, Bianca Sänger, Saskia M Burm, Eliana Stanganello, Vanessa M Spires, Fulvia Vascotto, Juliane Quinkhardt, Mustafa Diken, David P E Satijn, Sebastian Kreiter, Esther C W Breij

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activityResearch in context

    Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activityResearch in context oleh Ida H. Hiemstra, Kim C.M. Santegoets, Maarten L. Janmaat, Bart E.C.G. De Goeij, Wessel Ten Hagen, Sanne van Dooremalen, Peter Boross, Jeroen van den Brakel, Sieto Bosgra, Grietje Andringa, Berris van Kessel-Welmers, Dennis Verzijl, Richard G. Hibbert, Kristine A. Frerichs, Tuna Mutis, Niels W.C.J. van de Donk, Tahamtan Ahmadi, David Satijn, A. Kate Sasser, Esther C.W. Breij

    Diterbitkan 2023-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: